This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Trisomy 13, translocation13삼염색체증, 전위

Contents and key points
ItemDetails
A. Classification codesICD-10: Q91.6 | Special Copayment Reduction: V160 | Re-certification cycle: 5 years
B. SynonymsNone
C. Adult onsetAdult onset none — The translocation form, like the complete form, presents as a severe congenital malformation, and survival to adulthood is rare. However, it is clinically important that carriers of a parental balanced Robertsonian translocation (especially rob 13;14) are found in adults.
1. HistoryThe translocation form was recognized after the description of Patau syndrome. Familial rob(13;14) and its clinical significance were established.
2. CausesTrisomy of chromosome 13 due to unbalanced segregation in carriers of a Robertsonian translocation (mainly rob 13;14).
3. Genetics46 chromosomes but 3 copies of chromosome 13 material. rob(13;14) is the most common translocation. High risk of familial occurrence.
4. General epidemiologyAbout 10–15% of Patau syndrome. Proportion much higher than the translocation form of Edwards syndrome (1–2%).
5. Pathophysiology3:1 or 2:2 unbalanced segregation during meiosis in rob translocation carriers → offspring with excess chromosome 13 material.
6. SymptomsClinical picture identical to the complete form. Holoprosencephaly, polydactyly, cardiac malformations, facial malformations.
7. SignsSame physical signs as the complete form. The translocation form can be confirmed only by karyotype analysis.
8. ScreeningDetectable by serum screening and NIPT. Active screening recommended for families of rob translocation carriers.
9. DiagnosisTranslocation confirmed by standard karyotype. Parental karyotype analysis essential. FISH and CMA as adjuncts. rob(13;14)-specific testing.
10. TreatmentSame supportive care as the complete form. Genetic counseling and extended family screening are as important as treatment.
11. PrognosisPoor, same as the complete form. Management of familial recurrence risk is the key task related to prognosis.
12. PreventionAfter identification of a rob carrier, recurrence can be prevented by PGT-SR/PGT-T or prenatal diagnosis.
13. ReferencesPatau K (1960) and 9 others.

1. History

Trisomy 13 translocation form (translocation trisomy 13, Q91.6) has been classified as one of the three cytogenetic subtypes of Patau syndrome with advances in karyotyping technology since Patau syndrome was described in 1960. In particular, unlike the translocation form of Edwards syndrome (about 1–2%), the trisomy 13 translocation form accounts for about 10–15% of all Patau syndrome, making it a clinically very important subtype.

The main reason the clinical importance of the translocation form came to the fore is that the association between Robertsonian translocation and trisomy 13 was established. Chromosome 13 is one of the acrocentric chromosomes (chromosomes with rRNA genes and satellites on the short arm), and together with chromosomes 14, 15, 21, and 22 it is a major target of Robertsonian translocation. In a Robertsonian translocation, the short arms of two acrocentric chromosomes are lost and the long arms fuse to form a single translocation chromosome.

The most common translocation combination in the translocation form of Patau syndrome is rob(13;14), a translocation chromosome in which the long arms of chromosomes 13 and 14 are fused. The frequency of rob(13;14) balanced carriers is about 1/1,300, which is quite common, and it is one of the most common chromosomal structural abnormalities in humans. Because rob(13;14) balanced carriers are at risk of having offspring with Patau syndrome, genetic counseling and prenatal diagnosis are essential when this translocation is found.

In the 1970s–80s, with the spread of G-banding karyotype analysis, various translocation combinations other than rob(13;14), such as rob(13;13), rob(13;15), rob(13;21), and rob(13;22), were identified in the translocation form of Patau syndrome. Among these, rob(13;14) is the most common, and the centromeric fusion rob(13;13) (homologous translocation) is a special case with a recurrence risk of 100%, which is clinically very important.

Compared with the translocation form of Down syndrome (rob 14;21 or rob 21;21), the clinical role of rob(13;14) in the translocation form of Patau syndrome is equally important. In both cases there is a possibility of recurrence due to familial chromosomal structural abnormalities, and identification of balanced translocation carriers and prenatal diagnosis are key to prevention.


2. Causes

Most cases of the trisomy 13 translocation form (Q91.6) are caused by Robertsonian translocation. Robertsonian translocation is a structural chromosomal abnormality in which the short arms of two acrocentric chromosomes (chromosomes 13, 14, 15, 21, 22) are lost and the long arms fuse to form a single translocation chromosome. The translocation chromosome contains the long arms of both acrocentric chromosomes, and the rRNA genes on the short arms have sufficient copies on the other acrocentric chromosomes, so their loss has no clinical effect.

rob(13;14): A Robertsonian translocation chromosome formed by fusion of the long arms of chromosomes 13 and 14. The most common form of the translocation form of Patau syndrome. Balanced carrier karyotype: 45,XX,rob(13;14)(q10;q10) or 45,XY,rob(13;14). In balanced carriers, unbalanced segregation during meiosis can produce offspring with Patau syndrome.

rob(13;13): Formed by centromeric fusion of the long arms of the two copies of chromosome 13 (homologous Robertsonian translocation). Balanced carrier karyotype: 45,XX,rob(13;13)(q10;q10). In this case, all gametes produced by the carrier have either 2 copies (Robertsonian translocation) or 0 copies of chromosome 13 material, so normal offspring (2 copies) are impossible, and only Patau syndrome (3 copies) or monosomy 13 (0 copies, lethal) can occur. Therefore, the recurrence risk for rob(13;13) carriers is theoretically 100%, and in this case a very careful approach to genetic counseling and future pregnancy planning is required.

Other translocation combinations: rob(13;15), rob(13;21), rob(13;22), etc. are rarely reported. De novo translocation forms can also occur, and in this case the recurrence risk is low. Parental karyotype analysis is the key step to distinguish familial from sporadic cases.

The clinically most important special situation in the translocation form of Patau syndrome is the carrier of the rob(13;13) centromeric fusion. In this case, the birth of a normal child by natural conception is impossible, so implantation of normal embryos through assisted reproduction and PGT-SR becomes a realistic alternative.


3. Genetics

The most important feature of the genetics of the trisomy 13 translocation form is the pattern in which unbalanced offspring arise from a parent who is a carrier of a balanced Robertsonian translocation.

Meiotic segregation in balanced rob(13;14) carriers: In meiosis I of a rob(13;14) carrier, the translocation chromosome [rob(13;14)], the normal chromosome 13, and the normal chromosome 14 form a trivalent. Depending on the segregation pattern of this trivalent, the following offspring combinations are produced: (1) Alternate segregation: offspring with a normal karyotype [46,+13,+14] or a balanced carrier [45,rob(13;14)]. (2) Adjacent-1 segregation: offspring with an unbalanced karyotype [46,rob(13;14),+13 = Patau syndrome phenotype] or [45,−13 = lethal monosomy]. (3) Adjacent-2 segregation: offspring with an unbalanced karyotype [46,rob(13;14),+14] or [45,−14 = lethal]. (4) 3:0 segregation: occurs extremely rarely.

In practice, the empirical recurrence risk of offspring with Patau syndrome in rob(13;14) balanced carriers is lower than theoretical predictions (due to spontaneous loss of unbalanced offspring that cannot survive in utero). Risks of offspring with Patau syndrome of about 1–2% for maternal carriers and about 0.5–1% for paternal carriers have been reported empirically.

rob(13;13) centromeric fusion carriers: Normal offspring cannot be expected from 45,rob(13;13) carriers. The gametes produced are: (1) rob(13;13) translocation chromosome + normal sperm/egg → 46,rob(13;13),+13 offspring (Patau syndrome). (2) Gamete with 0 copies + normal sperm/egg → 45,−13 (lethal). Therefore, pregnancies of rob(13;13) carriers theoretically all end in Patau syndrome or early miscarriage. This is a very rare and serious situation in clinical genetics, and PGT-SR with donor embryos or adoption are the only alternatives.

Karyotype notation: The karyotype of a patient with the translocation form of Patau syndrome is written, for example, as 46,XX,+13,rob(13;14)(q10;q10) or 46,XY,der(13;14)(q10;q10),+13. The carrier parent is written as 45,XY,rob(13;14)(q10;q10).


4. General epidemiology

The trisomy 13 translocation form (Q91.6) accounts for about 10–15% of all Patau syndrome. This is 5–10 times the translocation form of Edwards syndrome (Q91.2, about 1–2%), and the difference is because chromosome 13 is a major target chromosome of Robertsonian translocation.

Frequency of balanced carriers of Robertsonian translocation rob(13;14): In the general population, the frequency of rob(13;14) balanced carriers is about 1/1,300, one of the most common balanced chromosomal structural abnormalities in humans. Considering this frequency, it is not uncommon for offspring with Patau syndrome to arise from rob(13;14) carrier parents.

Familial occurrence of the translocation form: In translocation Patau syndrome, some cases occur repeatedly in parents who are balanced translocation carriers, or multiple carrier members are identified within the same family. This is observed much more commonly than in the translocation form of Edwards syndrome. Therefore, when Patau syndrome occurs, confirming whether it is the translocation form and parental karyotype analysis are recommended even more strongly than for Edwards syndrome.

Maternal age: For the translocation form arising from balanced translocation carriers, the correlation with maternal age is low. Translocation Patau syndrome can occur in young mothers as well. For sporadic Robertsonian translocations, some studies suggest a weak correlation with maternal age, but the evidence is insufficient.

Cases of translocation Patau syndrome in Korea have been reported rarely. Families of rob(13;14) balanced carriers sometimes visit genetic counseling clinics, through which screening of family members and prenatal diagnosis plans are established. Cases of recurrence of translocation Patau syndrome within a family are also rarely reported in Korea.


5. Pathophysiology

The pathophysiology of the trisomy 13 translocation form is that unbalanced segregation (unbalanced segregation) during meiosis in a parent who is a Robertsonian translocation carrier forms an unbalanced karyotype in which chromosome 13 long-arm material is present in three copies.

Details of the mechanism in rob(13;14) carriers: The somatic cells of a carrier have 1 rob(13;14) translocation chromosome, 1 normal chromosome 13, and 1 normal chromosome 14, for a total of 45 chromosomes. In meiosis I, the rob(13;14) translocation chromosome, the normal chromosome 13, and the normal chromosome 14 form a trivalent, and various types of gametes are formed depending on how this trivalent segregates. When unbalanced segregation forms a diploid gamete containing both the rob(13;14) translocation chromosome + the normal chromosome 13 (including 2 copies of chromosome 13 long-arm material), fertilization with a normal gamete (1 copy of chromosome 13) produces offspring with a 46,rob(13;14),+13 karyotype (Patau syndrome). In the karyotype of this unbalanced offspring, the total chromosome number is 46, but chromosome 13 long-arm material amounts to 1 normal chromosome 13 + 1 chromosome 13 long arm within the rob(13;14) translocation = 2 or more copies, so a trisomy 13 effect occurs.

Gene dosage effect: In translocation Patau syndrome, chromosome 13 long-arm material is present in three copies (or the equivalent gene dosage), so global overexpression of chromosome 13 genes occurs just as in the complete form. Therefore, the clinical phenotype of the translocation form is identical to that of complete Patau syndrome.

Sporadic Robertsonian translocation: This is the case in which a new Robertsonian translocation arises during gamete formation even though the parental karyotypes are normal. It arises by non-allelic homologous recombination (NAHR) or random breakage and rejoining in the short-arm centromeric region of two acrocentric chromosomes. In sporadic translocations, the recurrence risk is low but not zero.

Formation of a rob(13;14) balanced translocation itself has no clinical phenotype because loss of the short arms is clinically silent, so carriers are healthy individuals with a normal phenotype. This translocation becomes a problem when unbalanced segregation during meiosis produces offspring with Patau syndrome or other unbalanced offspring.


6. Symptoms

The clinical symptoms of the trisomy 13 translocation form (Q91.6) are identical to those of complete Patau syndrome (Q91.4). Because chromosome 13 long-arm material is present in three copies, the same gene dosage effect as in the complete form occurs, and the same multiple congenital malformations appear.

Central nervous system malformations: Holoprosencephaly (HPE) occurs in about 50–70%. Alobar, semilobar, and lobar HPE may appear. Microcephaly, agenesis of the corpus callosum, and Dandy-Walker malformation also accompany it. Severe facial malformations due to HPE, such as cyclopia, median cleft lip, and proboscis, appear.

Facial malformations: Microphthalmia or anophthalmia and cleft lip and cleft palate are common. Low-set, malformed ears and ear abnormalities appear.

Polydactyly: Postaxial polydactyly is observed in about 60–80%. It can occur in both hands and feet.

Cardiovascular malformations: Congenital heart defects accompany in about 80%. VSD, PDA, ASD, DORV, etc. are common.

Genitourinary malformations: renal cysts, hydronephrosis, and renal dysplasia occur in about 50%.

Scalp defects: Localized skin defects of the scalp (cutis aplasia) are observed in about 20–30%.

Respiratory problems: Apneic episodes, appearing from the neonatal period, are a major cause of death.

Because the translocation form cannot be clinically distinguished from the complete form, the subtype of Patau syndrome cannot be determined from the clinical picture alone. Karyotype analysis is the only way to distinguish the subtypes.


7. Signs

The physical signs of translocation Patau syndrome are the same as those of the complete form. There are no physical signs specific to the translocation form. The main physical signs of Patau syndrome are described below.

Craniofacial signs: When holoprosencephaly is present, severe facial malformations such as cyclopia (fused orbits), proboscis, and median cleft lip are observed. Microphthalmia or anophthalmia occurs in about 50–70%. Microcephaly, low-set malformed ears, and cleft lip and cleft palate are common.

Scalp defects: Localized skin defects of the scalp are observed in about 20–30%. This is a relatively specific finding of Patau syndrome.

Limb signs: Postaxial polydactyly (extra fingers/toes on the little-finger side) is observed in 60–80%. Clubfoot or finger contractures may occur.

Cardiac signs: heart murmur, cyanosis, and signs of heart failure may appear.

Muscle tone signs: Hypotonia, weak sucking reflex, and seizures occur.

Prenatal ultrasound: Holoprosencephaly (single ventricle, fused orbits), microphthalmia, polydactyly, cardiac malformations, and renal cysts are detected. The translocation form shows the same ultrasound findings as the complete form, so it cannot be distinguished from the complete form by ultrasound. NIPT can detect trisomy of chromosome 13, but NIPT cannot distinguish the translocation form from the complete form, so karyotype analysis is essential.

Karyotype findings: The total chromosome number is 46, but the rob translocation chromosome is seen as abnormally large. Chromosome 13 material is present in three copies: the normal chromosome 13 and the chromosome 13 long arm within the translocation chromosome. Parental karyotypes are examined to determine whether a parent is a carrier of a balanced Robertsonian translocation.


8. Screening

Prenatal screening for translocation Patau syndrome is performed similarly to the complete form. However, active screening is needed that takes into account the possibility of familial occurrence specific to the translocation form.

NIPT (cfDNA): In the translocation form as well, an excess signal of chromosome 13 material can be detected, so NIPT is useful. However, NIPT results alone cannot distinguish the complete form from the translocation form, so a positive result must be confirmed by karyotype analysis.

Maternal serum screening: In the translocation form as well, a pattern of abnormal serum markers similar to that of the complete form may appear.

Prenatal ultrasound: When holoprosencephaly, polydactyly, microphthalmia, cardiac malformations, etc. are detected on ultrasound, invasive testing is performed with suspicion of trisomy 13. The translocation form shows the same ultrasound findings as the complete form.

Screening of families of balanced translocation carriers: When, after a diagnosis of translocation Patau syndrome in a previous pregnancy, parental karyotype analysis identifies a carrier of rob(13;14) or another chromosome 13-related Robertsonian translocation, invasive karyotype analysis must be performed in the next pregnancy, and carrier screening of that carrier's siblings and family is recommended. This is the key element that most distinguishes screening for translocation Patau syndrome from the complete form.

Special situation of rob(13;13) centromeric fusion carriers: In female rob(13;13) carriers, the birth of a normal child by natural conception is impossible, so PGT-SR counseling and planning must be undertaken before pregnancy. This is a situation requiring special attention in clinical genetics.

After birth: In newborns showing clinical findings of Patau syndrome, karyotype analysis is used to determine whether it is the translocation form. If the translocation form is confirmed, parental karyotype analysis is performed immediately.


9. Diagnosis

The key to diagnosing translocation trisomy 13 is to confirm the translocation structure by standard karyotype analysis and to always perform parental karyotype analysis. Because the proportion of the translocation form in Patau syndrome is high at 10–15%, it is essential in all patients with Patau syndrome to distinguish the complete form from the translocation form by karyotype analysis.

Standard G-banding karyotype analysis: High-resolution G-banding karyotype analysis is performed prenatally after CVS or amniocentesis, and after birth on peripheral blood. In the translocation form, the total chromosome number is 46, but an abnormally large Robertsonian translocation chromosome is observed. It is important to define the exact translocation structure (the long arms of which two acrocentric chromosomes are fused).

FISH: Using probes specific to chromosome 13 and chromosome 14 (or another translocation partner), the translocation structure is visually confirmed and the copy number of chromosome 13 material is accurately determined.

Chromosomal microarray (CMA): SNP array precisely defines the chromosome 13 trisomic region and abnormalities of the translocation partner chromosome. It is also useful for detecting additional genomic imbalances.

Parental karyotype analysis (essential): When the translocation form is confirmed, G-banding karyotype analysis of peripheral blood from both parents is absolutely necessary. When a parent is found to be a balanced Robertsonian translocation carrier [especially rob(13;14) or rob(13;13)], recurrence risk counseling, extended family screening, and a prenatal diagnosis plan are established immediately. Carriers of the rob(13;13) centromeric fusion need special genetic counseling.

Extended family screening: Carrier karyotype analysis is recommended for family members such as the siblings of the balanced carrier parent and the parents' parents (grandparents). Family members identified as carriers are offered genetic counseling and prenatal diagnosis options.


10. Treatment

As with the complete form, treatment of translocation Patau syndrome cannot correct the underlying chromosomal abnormality, so it is based on multidisciplinary supportive care. However, in the translocation form, alongside treatment of the patient, genetic counseling for the family and support for future pregnancy planning are tasks as important as treatment.

Neonatal intensive care and palliative care: Neonatal intensive care and palliative care are provided as in complete Patau syndrome. The intensity of treatment is decided through shared decision-making between the multidisciplinary team and the family.

Seizure management: Neonatal seizures are controlled with anticonvulsants (phenobarbital, levetiracetam).

Nutritional support: Nutrition via tube feeding or gastrostomy is needed.

Treatment of cardiac malformations: The indications for cardiac surgery are individualized and decided by the multidisciplinary team and the family.

Genetic counseling and family support (key): In the translocation form, genetic counseling and family support are as important as treatment. The recurrence risk is explained according to the parental karyotype results, and future pregnancy planning (PGT-SR or PGT-T, prenatal diagnosis) is specifically guided. For carriers of the rob(13;13) centromeric fusion, it is thoroughly explained that the birth of a normal child by natural conception is impossible, and all alternatives, including PGT-SR, are presented.

Linkage to extended family screening: Carrier screening of family members of the balanced carrier parent is recommended, and positive individuals are provided with a referral to genetic counseling. Preventing recurrence of Patau syndrome within the family in this way is the most important clinical action after diagnosing a child with the translocation form.


11. Prognosis

The survival prognosis of the trisomy 13 translocation form (Q91.6) is very poor, the same as the complete form (Q91.4), when the entire long arm of chromosome 13 is present in three copies. The median survival is about 7–10 days, and the 1-year survival rate is around 5–10%. The main causes of death are apnea, heart failure, and respiratory failure.

Because the phenotype of the translocation form is identical to the complete form, the clinical course of an individual patient is also similar to the complete form. The severity of holoprosencephaly (alobar worst, lobar relatively better) and the severity of cardiac malformations are the main factors determining individual prognosis.

Genetic prognosis (familial recurrence risk): The clinically most important prognosis-related information in the translocation form is the recurrence risk within the family. For parents who are balanced rob(13;14) carriers, the risk of having offspring with Patau syndrome in each pregnancy is 1–2% maternal and 0.5–1% paternal, and the frequency of spontaneous miscarriage also increases. In carriers of the rob(13;13) centromeric fusion, the birth of a normal child is impossible.

For parents identified as balanced translocation carriers, it is possible to prevent recurrence of Patau syndrome through PGT-SR or prenatal diagnosis. This is the most meaningful clinical contribution that can be offered to the family after a diagnosis of translocation Patau syndrome.


12. Prevention

The key point of prevention of the trisomy 13 translocation form that most differs from the complete form is that active prevention is possible when a balanced Robertsonian translocation carrier is identified.

Parental karyotype analysis and carrier identification: When translocation Patau syndrome is diagnosed, parental karyotype analysis must be performed to determine whether a parent is a carrier of rob(13;14) or another chromosome 13-related Robertsonian translocation.

Preimplantation genetic testing (PGT-SR): When parents who are balanced Robertsonian translocation carriers undergo assisted reproduction, PGT-SR is performed to detect unbalanced karyotypes (including Patau syndrome) at the embryo stage and prevent their implantation. For carriers of the rob(13;13) centromeric fusion, PGT-SR is the only practical means of prevention.

Prenatal genetic diagnosis: In each pregnancy of parents who are balanced translocation carriers, the fetal chromosomal status is confirmed by karyotype analysis via CVS or amniocentesis.

Extended family screening: Karyotype analysis is recommended for the siblings and other family members of parents who are balanced translocation carriers. In this way, all carriers within the family are identified early and prenatal diagnosis plans are established. This is the most effective approach to preventing recurrence of Patau syndrome.

Genetic counseling: Families with translocation Patau syndrome are provided with structured genetic counseling that thoroughly explains the mechanism of Robertsonian translocation, the meaning of being a carrier, the recurrence risk (in particular, affected offspring in 100% for rob(13;13) carriers), prenatal diagnosis options, and the possibility of PGT-SR.


13. References

  1. Patau K, Smith DW, Therman E, Inhorn SL, Wagner HP. Multiple congenital anomaly caused by an extra autosome. Lancet. 1960;1(7128):790-793. DOI: 10.1016/S0140-6736(60)90676-0. PMID: 13819420.
  2. Gardner RJM, Sutherland GR, Shaffer LG. Chromosome Abnormalities and Genetic Counseling. 4th ed. Oxford: Oxford University Press; 2011.
  3. Therman E, Susman B, Denniston C. The nonrandom participation of human acrocentric chromosomes in Robertsonian translocations. Ann Hum Genet. 1989;53(Pt 1):49-65. DOI: 10.1111/j.1469-1809.1989.tb01121.x. PMID: 2660539.
  4. Hamerton JL, Canning N, Ray M, Smith S. A cytogenetic survey of 14,069 newborn infants. I. Incidence of chromosome abnormalities. Clin Genet. 1975;8(4):223-243. DOI: 10.1111/j.1399-0004.1975.tb01498.x. PMID: 1183067.
  5. Springett A, Wellesley D, Greenlees R, et al. Congenital anomalies associated with trisomy 18 or trisomy 13: a registry-based study in 16 European countries, 2000-2011. Am J Med Genet A. 2015;167A(12):3062-3069. DOI: 10.1002/ajmg.a.37355. PMID: 26264653.
  6. Rasmussen SA, Wong LYC, Yang Q, May KM, Friedman JM. Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics. 2003;111(4):777-784. DOI: 10.1542/peds.111.4.777. PMID: 12671111.
  7. Baty BJ, Blackburn BL, Carey JC. Natural history of trisomy 18 and trisomy 13. I. Growth, physical assessment, medical histories, survival and recurrence risk. Am J Med Genet. 1994;49(2):175-188. DOI: 10.1002/ajmg.1320490208. PMID: 8116662.
  8. Kosiv KA, Gossett JM, Bai S, Collins RT 2nd. Congenital heart surgery on in-hospital mortality in trisomy 13 and 18. Pediatrics. 2017;140(5):e20170136. DOI: 10.1542/peds.2017-0136. PMID: 29061895.
  9. Wimalasundera RC, Gardiner HM. Congenital heart disease and aneuploidy. Prenat Diagn. 2004;24(13):1116-1122. DOI: 10.1002/pd.1086. PMID: 15614842.
  10. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Ultrasound Obstet Gynecol. 2017;49(5):571-580. DOI: 10.1002/uog.17244. PMID: 27743430.